Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. - Blackwell, K. L.; Pegram, M. D.; Tan-Chiu, E.; Schwartzberg, L. S.; Arbushites, M. C.; Maltzman, J. D.; Forster, J. K.; Rubin, S. D.; Stein, S. H.; Burstein, H. J. (Annals of Oncology, 2009)